<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85754">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02013050</url>
  </required_header>
  <id_info>
    <org_study_id>IDR-OM-01</org_study_id>
    <nct_id>NCT02013050</nct_id>
  </id_info>
  <brief_title>A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer</brief_title>
  <official_title>A Phase 2,Double-Blind, Randomized, Placebo-Controlled, Dose Escalating, Multicenter Study of SGX942 For the Attenuation of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soligenix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soligenix</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of SGX942 in patients receiving chemoradiation treatment
      for the treatment of head and neck cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Oral Mucositis Symptoms</measure>
    <time_frame>4 weeks after end of therapy</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Oral Mucositis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SGX942</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational Drug i) 1.5 mg/kg ii) 3.0 mg/kg iii) 6.0 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGX942</intervention_name>
    <arm_group_label>SGX942</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy-proven non-metastatic squamous cell carcinoma of the mouth or
             oropharynx and is planned to receive a standard course of concomitant CRT.

          -  Patients who have received surgery are eligible if surgery is performed within 6
             weeks prior to study initiation.

          -  Planned to receive standard cisplatin chemotherapy administered either weekly or
             every third week.

          -  Must be able to read and understand informed consent

          -  Adequate birth control methods for the duration of the study

        Exclusion Criteria:

          -  Current mucositis.

          -  Prior radiation to the head and neck.

          -  Chemotherapy treatment within the previous 12 months.

          -  Tumors of the lips, sinuses, salivary glands or nasopharynx.

          -  Unknown primary tumor.

          -  Stage 4c metastases.

          -  Evidence of significant hepatic, hematologic, or immunologic disease.

          -  Women who are pregnant or breast-feeding.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Adam Rumage</last_name>
    <phone>609-538-8200</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Markey Cancer Center-University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mahesh Kudrimoti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 7, 2014</lastchanged_date>
  <firstreceived_date>December 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
    <mesh_term>Mucositis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
